These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35589447)

  • 1. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.
    Goebel GL; Qiu X; Wu P
    Trends Pharmacol Sci; 2022 Oct; 43(10):866-881. PubMed ID: 35589447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in kinase drug discovery: targets, indications and inhibitor design.
    Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB
    Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
    Wu P; Nielsen TE; Clausen MH
    Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
    Lu X; Smaill JB; Ding K
    J Med Chem; 2020 Oct; 63(19):10726-10741. PubMed ID: 32432477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I.
    Wang Y; Nan X; Duan Y; Wang Q; Liang Z; Yin H
    Bioorg Med Chem; 2024 Sep; 111():117870. PubMed ID: 39128361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors.
    Du J; Yan H; Xu Z; Yang B; He Q; Wang X; Luo P
    Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1311-1325. PubMed ID: 34743659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Updated Review on Developing Small Molecule Kinase Inhibitors Using Computer-Aided Drug Design Approaches.
    Li L; Liu S; Wang B; Liu F; Xu S; Li P; Chen Y
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA-approved small-molecule kinase inhibitors.
    Wu P; Nielsen TE; Clausen MH
    Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perturbation of biological processes with small molecule kinase inhibitors.
    Li W; Wang J; Liang R; Lei X
    Curr Opin Chem Biol; 2022 Oct; 70():102185. PubMed ID: 35853282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric small-molecule kinase inhibitors.
    Wu P; Clausen MH; Nielsen TE
    Pharmacol Ther; 2015 Dec; 156():59-68. PubMed ID: 26478442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors.
    Jin Y; Xu Z; Yan H; He Q; Yang X; Luo P
    Front Pharmacol; 2020; 11():891. PubMed ID: 32595510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors.
    Olaharski AJ; Gonzaludo N; Bitter H; Goldstein D; Kirchner S; Uppal H; Kolaja K
    PLoS Comput Biol; 2009 Jul; 5(7):e1000446. PubMed ID: 19629159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
    Latham BD; Geffert RM; Jackson KD
    Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy.
    Groppe JC
    Expert Opin Drug Discov; 2019 Dec; 14(12):1237-1253. PubMed ID: 31513432
    [No Abstract]   [Full Text] [Related]  

  • 16. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity of FDA-approved small molecule kinase inhibitors.
    Jiang H; Jin Y; Yan H; Xu Z; Yang B; He Q; Luo P
    Expert Opin Drug Saf; 2021 Mar; 20(3):335-348. PubMed ID: 33356646
    [No Abstract]   [Full Text] [Related]  

  • 19. Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.
    Zarakas MA; Desai JV; Chamilos G; Lionakis MS
    Curr Fungal Infect Rep; 2019 Sep; 13(3):86-98. PubMed ID: 31555394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
    Fasano M; Della Corte CM; Califano R; Capuano A; Troiani T; Martinelli E; Ciardiello F; Morgillo F
    Expert Opin Investig Drugs; 2014 Jun; 23(6):809-21. PubMed ID: 24673358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.